Acquiring Company
Aurobindo Pharma Limited
Acquired Company
A1 Biochem Group
Description
Aurobindo Pharma Limited's subsidiary, Apitoria Pharma, has acquired an 80% stake in A1 Biochem Group's CRO business for USD 17 million. This acquisition will enable Aurobindo to enhance its research and development capabilities while expanding its presence in the Active Pharmaceutical Ingredients market. The deal is expected to close within 90 to 120 days, pending regulatory approvals.
Fundz sees it the moment Aurobindo Pharma Limited makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired A1 Biochem Group?
A1 Biochem Group was acquired by Aurobindo Pharma Limited, based in United States. The deal was reported on July 26, 2026. Aurobindo Pharma Limited is a Midcap Pharma stock engaged in the manufacturing and marketing of APIs, generic pharmaceuticals, and other related services. Aurobindo Pharma Limited is privately held and operates in Manufacturing.
When did Aurobindo Pharma Limited acquire A1 Biochem Group?
Aurobindo Pharma Limited's acquisition of A1 Biochem Group was reported on July 26, 2026. Aurobindo Pharma Limited's subsidiary, Apitoria Pharma, has acquired an 80% stake in A1 Biochem Group's CRO business for USD 17 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does A1 Biochem Group do?
A1 Biochem Group is a Contract Research Organization (CRO) that offers comprehensive chemistry services to pharmaceutical companies and academic institutions. It is privately held, operating in Biotechnology, and is based in Hyderabad.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.